NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Regulation FD DisclosureItem 7.01.Regulation FD Disclosure
On July 18, 2017, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing topline data from an oral Human Abuse Potential (HAP) study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain. A copy of the Press Release reporting results from the HAP study is furnished herewith as Exhibit 99.1.
In the Press Release, Nektar announced that it would hold a Webcast conference call on July 18, 2017 at 5:45 a.m. (Pacific Time)/8:45 a.m. (Eastern Time) to review the results from the HAP study. This conference call is accessible through a link that is posted on the home page and Investor section of the Nektar website: http://www.nektar.com.
The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01.Financial Statements and Exhibits.
|99.1||Press Release titled “Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain” issued by Nektar Therapeutics on July 18, 2017.|
NEKTAR THERAPEUTICS ExhibitEX-99.1 2 s106841_ex99-1.htm EXHIBIT 99-1 Exhibit 99.1 Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181,…To view the full exhibit click
About NEKTAR THERAPEUTICS (NASDAQ:NKTR)
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).